BridgeMD
New treatment option for Liver Cancer
Official title Unravelling the Impact of Radiofrecuency in Liver Surgery: the Key to Decrease Local Recurrence?
ClinicalTrials.gov ID: NCT05492136
What this study is testing
- What it's testing
- Radiofrequency devices have been increasingly employed in liver surgery in order to achieve proper hemostasis and this use has become more evident with the implementation of minimal invasive surgery. Due to its well-known efficacy for tumor ablation (i.e.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Written informed consent granted prior to the initiation of the surgical procedure, given with the understanding that the patient has the right to...
- 18 year of age or older.
- WHO performance scale 0-2
- Consecutive patients (both sexes equally distributed) suffering from CRLM confirmed either by abdominal CT, abdominal MRI or/and by...
- Any previous chemotherapy regime is permitted.
You likely can't join if
- Previous or concurrent cancer that is distinct from one primary tumor of which the Liver metastasis comes from EXCEPT cervical carcinoma in situ...
- Any cancer curatively treated \> 3 years prior to enrollment is permitted.
- ASA 4.
- Non-resectable extrahepatic metastases.
- Liver metastasis from other origin apart from colorectal.
- Bening primary tumor of the liver.
See the full eligibility criteria
- Written informed consent granted prior to the initiation of the surgical procedure, given with the understanding that the patient has the right to withdraw from the study at any time, without prejudice.
- 18 year of age or older.
- WHO performance scale 0-2
- Consecutive patients (both sexes equally distributed) suffering from CRLM confirmed either by abdominal CT, abdominal MRI or/and by histologic-cytological evaluation or patients suffering from HCC.
- Any previous chemotherapy regime is permitted.
- ASA score 1 to 3.
- Previous or concurrent cancer that is distinct from one primary tumor of which the Liver metastasis comes from EXCEPT cervical carcinoma in situ, treated basal cell carcinoma, superficial bladder tumors (Ta, Tis \& T1).
- Any cancer curatively treated \> 3 years prior to enrollment is permitted.
- ASA 4.
- Non-resectable extrahepatic metastases.
- Liver metastasis from other origin apart from colorectal.
- Bening primary tumor of the liver.
- Pregnant woman.
- Participation in another clinical trial.
The study team makes the final eligibility decision.
Where it's taking place
- Barcelona, Spain
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Barcelona, Spain. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.